OMTX705 Conjugado Anticuerpo-Fármaco

The in vivo antitumoral efficacy of Oncomatryx Anti-MTX5:Cytolysin ADC, OMTX705, was tested at two different laboratories, in several different pancreatic cancer patient-derived subcutaneous xenograft murine models.

OMTX705 led to 100% tumor growth inhibition as single agent and even tumor regression when combined with Gemcitabine and/or Abraxane.

 

MTX5MTX5

No mice weight loss occurred when administering OMTX705-558, as single agent or in combination with Gemcitabine and/or abraxane.

 

MTX5

MTX5

The in vivo antitumoral efficacy of Oncomatryx Cytolysin ADC, OMTX705, was tested at two different laboratories, in several different pancreatic cancer patient-derived subcutaneous xenograft murine models.

OMTX705-558 led to 100% tumor growth inhibition as single agent and even tumor regression when combined with Gemcitabine and/or Abraxane.

 

MTX5MTX5

No mice weight loss occurred when administering OMTX705, as single agent or in combination with Gemcitabine and/or abraxane.

 

MTX5

MTX5

Continuando utilizando está página acepta el uso de cookies. Continúe, haga scroll o acepte más información

Los ajustes de cookies de esta página están configurados como "aceptar cookies" para ofrecer una mejor experiencia de navegación. Si continúa usando el sitio o hace clic en "acepto" está permitiendo su uso.

Cerrar